US Stock Market Move | Due to the failure of a competitor's drug development to meet its goals, Vertex Pharmaceuticals Incorporated (VRTX.US) rose nearly 7%.

On Monday, Vertex Pharmaceuticals Incorporated (VRTX.US) surged nearly 7% in early trading, hitting a record high; meanwhile, competitor Sionna Therapeutics (SION.US) plummeted over 90%, reaching a record low. In news, SION announced that it would terminate the development of its experimental cystic fibrosis drug SION-719 after it failed to meet primary endpoints in a mid-stage clinical trial. Investors had previously been concerned that SION might pose a threat to VRTX's core cystic fibrosis business, but the failure of this trial has alleviated those concerns. The products Trikafta and Alyftrek sold by VRTX are used to treat cystic fibrosisa rare, chronic genetic disease that shortens life expectancy and leads to progressive damage to the lungs.